Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors while in the central nervous method, conolidine modulates alternate molecular targets. A Science Advancements analyze found that conolidine interacts While using the atypical chemokine receptor ACKR3/CX